295 related articles for article (PubMed ID: 10662392)
1. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
Baltussen R; Leidl R; Ament A
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
[TBL] [Abstract][Full Text] [Related]
2. Making cost assessments based on RCTs more useful to decision-makers.
Baltussen R; Ament A; Leidl R
Health Policy; 1996 Sep; 37(3):163-83. PubMed ID: 10160021
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
4. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
[TBL] [Abstract][Full Text] [Related]
6. Bridging the gap: exploring the barriers to using economic evidence in healthcare decision making and strategies for improving uptake.
Merlo G; Page K; Ratcliffe J; Halton K; Graves N
Appl Health Econ Health Policy; 2015 Jun; 13(3):303-9. PubMed ID: 25288052
[TBL] [Abstract][Full Text] [Related]
7. The problem of protocol driven costs in pharmacoeconomic analysis.
Coyle D; Lee KM
Pharmacoeconomics; 1998 Oct; 14(4):357-63. PubMed ID: 10344904
[TBL] [Abstract][Full Text] [Related]
8. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
[TBL] [Abstract][Full Text] [Related]
9. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.
Blommestein HM; Franken MG; Uyl-de Groot CA
Pharmacoeconomics; 2015 Jun; 33(6):551-60. PubMed ID: 25644460
[TBL] [Abstract][Full Text] [Related]
10. Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries: can locally generated observational study data overcome methodological limitations?
Baik S; Chacra AR; Yuxiu L; White J; Güler S; Latif ZA
Diabetes Res Clin Pract; 2010 May; 88 Suppl 1():S17-22. PubMed ID: 20466164
[TBL] [Abstract][Full Text] [Related]
11. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
12. Review of health economics modelling in rheumatoid arthritis.
Emery P
Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
[TBL] [Abstract][Full Text] [Related]
13. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
14. The use of claims databases for outcomes research: rationale, challenges, and strategies.
Motheral BR; Fairman KA
Clin Ther; 1997; 19(2):346-66. PubMed ID: 9152572
[TBL] [Abstract][Full Text] [Related]
15. Modelling in the economic evaluation of health care: selecting the appropriate approach.
Barton P; Bryan S; Robinson S
J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
[TBL] [Abstract][Full Text] [Related]
16. An illustration of the modelling of cost and efficacy data from a clinical trial.
Hahn S; Whitehead A
Stat Med; 2003 Mar; 22(6):1009-24. PubMed ID: 12627415
[TBL] [Abstract][Full Text] [Related]
17. Approaches to economic evaluation in telemedicine.
Bergmo TS
J Telemed Telecare; 2012 Jun; 18(4):181-4. PubMed ID: 22619374
[TBL] [Abstract][Full Text] [Related]
18. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.
Bodrogi J; Kaló Z
Br J Pharmacol; 2010 Apr; 159(7):1367-73. PubMed ID: 20132213
[TBL] [Abstract][Full Text] [Related]
19. Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making.
Drummond M; Brown R; Fendrick AM; Fullerton P; Neumann P; Taylor R; Barbieri M;
Value Health; 2003; 6(4):407-16. PubMed ID: 12859580
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
